Navigation Links
Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Date:12/5/2012

PHILADELPHIA, Dec. 5, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced  a preview of its newest intelligence solution, Thomson Reuters Cortellis™ for Clinical Trials Intelligence. Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information necessary to evaluate market opportunities, identify potential barriers, and establish informed decisions about clinical trial design and operations. 

Cortellis for Clinical Trials Intelligence is the latest information solution offered through Thomson Reuters Cortellis, the industry's premier Life Sciences information delivery platform. It has the broadest remit of any clinical trials database including a 45-year history of clinical outcomes, as well as the latest market competitive activity from established and emerging markets such as China, India and Brazil. It is the only solution that enables a customer to integrate their proprietary research data with comprehensive clinical trials protocols and outcomes, drug pipeline, biomarker, regulatory, financial and patent information from Thomson Reuters. With its integrated analytics tools and visualizations, users will have greater opportunities to maximize the value of clinical trial content to inform internal strategy and decision-making.  

"Cortellis for Clinical Trials Intelligence provides comprehensive clinical trial protocols and outcomes with global reach and integrates with other key intelligence areas – such as patents and literature – to allow for the broadest possible perspectives and actionable insights," said Jon Brett-Harris, executive vice president at Thomson Reuters. "However, it is not just an information web portal. We are also providing multiple delivery options, such as dynamic real-time visualizations, iPad support and application programming interfaces to assist our customers in integrating it with their existing knowledge platforms and workflow solutions."

Cortellis for Clinical Trials Intelligence optimizes critical clinical trial functions by equipping R&D strategists with knowledge that helps them discover market opportunities and potential barriers. This solution enables efficient searching for competing trials as well as identifying countries rich in target populations. By empowering clinical development teams to better understand trial design trends, Cortellis for Clinical Trials Intelligence allows them to design better and faster trials, while enabling marketing teams to pinpoint likely competitors.

The experts of Thomson Reuters' professional services also utilize Cortellis for Clinical Trial Intelligence and the company's other intelligence solutions – including translational medicine offerings and clinical development and portfolio strategy benchmarking – to support specific customer projects. Thomson Reuters has more than 15 years of experience supporting clinical development in the optimization of global clinical performance metrics, analysis and trending through its business, CMR International.

For more information on Cortellis, visit cortellis.thomsonreuters.com.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
2. Thomson Reuters Finds Increase in New Research for Neglected Tropical Diseases
3. Thomson Reuters Speeds Regulatory Decision Making with New Pharmaceutical Intelligence Solution
4. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
5. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
6. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
7. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
8. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple ... picturesque Babcock Cove, recently received training and certification in Closed Pulse Irrigation™ ... a prestigious five-star rating from the Centers for Medicare and Medicaid Services, to have ...
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story ... is the creation of published author, Larry R. Sherman, a retired chemistry professor from ... religion, as well as four novels. , Though the book opens in 1947, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s ... and neglect, and the struggles faced while hoping for a better life. “Without ... author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “Glimpses Of Light”: ... of the world. “Glimpses Of Light” is the creation of published author, J.M. Shepherd, ... in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is one ...
(Date:8/22/2017)... ... 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, ... stress of modern life continually makes more demands on time and energy, people are ... trap people in vicious high/low cycles and can also cause long term health issues. ...
Breaking Medicine News(10 mins):